Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: Results of the CANWARD 2007-2009 study

Patricia J. Simner, George G. Zhanel, Johann Pitout, Franil Tailor, Melissa McCracken, Michael R. Mulvey, Philippe R.S. Lagacé-Wiens, Heather J. Adam, Daryl J. Hoban

Research output: Contribution to journalArticlepeer-review

Abstract

The national prevalence of extended-spectrum β-lactamase (ESBL)-producing (2007: 3.4%, 2008: 4.9%, 2009: 4.3%) and AmpC β-lactamase (AmpC)-producing (2007: 0.8%, 2008: 3.2%, 2009: 2.7%) Escherichia coli in Canadian hospitals have fluctuated from 2007 to 2009. Rates of co-resistance to non-lactam agents are elevated, and multidrug-resistant (MDR) phenotype were observed among E. coli strains producing ESBLs (83.3% MDR) and AmpCs (31.0%). The majority (>98%) of isolates remained susceptible to colistin, tigecycline, amikacin, and the carbapenems. CMY-2 encoding gene was detected in 52.9% of AmpC-producing strains, while blaCTX-M-15 (65.2%) was the predominant ESBL genotype. A total of 50.3% of ESBL-producing E. coli and 21.4% of AmpC producers belonged to the ST131 clone. In conclusion, ESBL- and AmpC-producing E. coli are established in Canadian hospitals; and although the prevalence rates of these isolates remain low, they are often MDR and associated with the ST131 clone.

Original languageEnglish (US)
Pages (from-to)326-334
Number of pages9
JournalDiagnostic Microbiology and Infectious Disease
Volume69
Issue number3
DOIs
StatePublished - Mar 1 2011
Externally publishedYes

Keywords

  • AmpC
  • E. coli
  • ESBL

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: Results of the CANWARD 2007-2009 study'. Together they form a unique fingerprint.

Cite this